The U.S. FDA approved a new medication called Cobenfy by Bristol Myers Squibb to treat schizophrenia by stimulating brain receptors. The approval comes as current antipsychotics are only effective in half of patients and often have side effects. The Biden administration abandoned a proposal to require drug companies to disclose prices and research costs, due to pressure from pharmaceutical companies and lobbying groups threatening legal action. This decision highlights the administration’s reluctance to challenge the powerful industry. The move also follows a Supreme Court decision making it easier for the health care industry to litigate against federal rules they disagree with.
Source link
STAT+: Pharmalittle: We’re reading about a new schizophrenia drug, a U.N. pledge on AMR and more
